布地奈德联合氢化可的松琥珀酸钠治疗儿童支气管肺炎的效果评价
|
摘要
目的:探讨布地奈德联合氢化可的松琥珀酸钠治疗儿童支气管肺炎的效果及对患儿炎症指标的影响。方法 :选取2016年8月—2017年8月我院收治的支气管肺炎患儿80例,按照随机数字表法分为研究组与对照组,各40例。对照组应用布地奈德(1 mg与3 mL0.9%氯化钠注射液混匀后雾化吸入,tid)治疗,研究组在对照组基础上联合应用氢化可的松琥珀酸钠(5～10 mg溶于300 mL葡萄糖注射液中静脉滴注,qd)治疗。比较两组治疗效果、肺功能[包括第1秒用力呼气容积(FEV_1)、FEV_1百分比(FEV_1%)、FEV_1同肺活量(FVC)的比值(FEV_1/FVC)以及6 min步行试验(6MWT)]以及血清炎性因子指标[血清肿瘤坏死因子(TNF)-α、白细胞介素(IL)-6、C-反应蛋白(CRP)]。结果:研究组有效率显著高于对照组,差异有统计学意义(P <0.05);治疗后研究组肺功能指标均明显优于对照组,血清炎性因子水平均明显低于对照组,差异有统计学意义(P <0.05)。结论 :联合布地奈德和氢化可的松琥珀酸钠治疗儿童支气管肺炎的疗效显著,能有效改善肺功能,降低血清炎性因子水平,值得进一步推广应用。
Objective: To investigate the effect of budesonide combined with hydrocortisone sodium succinate in the treatment of bronchial pneumonia in children and its effect on children's inflammation indexes. Methods: 80 children with bronchial pneumonia admitted to our hospital from August 2016 to August 2017 were selected and randomly divided into a study group and a control group, 40 cases each. The children in the control group were treated with budesonide(1 mg drug was mixed with 3 mL 0.9% sodium chloride injection and then inhaled, tid), and the children in the study group were further treated with hydrocortisone sodium succinate(5～10 mg drug was dissolved in 300 mL glucose injection for intravenous infusion, qd). The treatment effect, lung functions [including forced expiratory volume in 1 second(FEV_1), percentage of FEV_1(FEV_1%), ratio of FEV_1 to vital capacity(FVC)(FEV_1/FVC) and 6 min walk test(6 MWT)] and serum inflammatory factor indexes [serum tumor necrosis factor(TNF)-α, interleukin(IL)-6, C-reactive protein(CRP)] were compared between the two groups. Results: The effective rate in the study group was significantly higher than that in the control group, and the difference was statistically significant(P<0.05). After treatment, the lung function indexes in the study group were significantly better than those in the control group, and the serum inflammatory factor levels were significantly lower than those in the control group, with statistically significant differences(P<0.05). Conclusion:Budesonide combined with hydrocortisone sodium succinate is significantly effective in the treatment of bronchial pneumonia in children, which can effectively improve lung functions and reduce serum inflammatory factor levels, and is worthy of further application.
Objective: To investigate the effect of budesonide combined with hydrocortisone sodium succinate in the treatment of bronchial pneumonia in children and its effect on children's inflammation indexes. Methods: 80 children with bronchial pneumonia admitted to our hospital from August 2016 to August 2017 were selected and randomly divided into a study group and a control group, 40 cases each. The children in the control group were treated with budesonide(1 mg drug was mixed with 3 mL 0.9% sodium chloride injection and then inhaled, tid), and the children in the study group were further treated with hydrocortisone sodium succinate(5～10 mg drug was dissolved in 300 mL glucose injection for intravenous infusion, qd). The treatment effect, lung functions [including forced expiratory volume in 1 second(FEV_1), percentage of FEV_1(FEV_1%), ratio of FEV_1 to vital capacity(FVC)(FEV_1/FVC) and 6 min walk test(6 MWT)] and serum inflammatory factor indexes [serum tumor necrosis factor(TNF)-α, interleukin(IL)-6, C-reactive protein(CRP)] were compared between the two groups. Results: The effective rate in the study group was significantly higher than that in the control group, and the difference was statistically significant(P<0.05). After treatment, the lung function indexes in the study group were significantly better than those in the control group, and the serum inflammatory factor levels were significantly lower than those in the control group, with statistically significant differences(P<0.05). Conclusion:Budesonide combined with hydrocortisone sodium succinate is significantly effective in the treatment of bronchial pneumonia in children, which can effectively improve lung functions and reduce serum inflammatory factor levels, and is worthy of further application.
引文
[1]陈燕燕.喜炎平注射液联合特布他林、布地奈德雾化吸入治疗儿童支气管肺炎的效果及对炎症指标的影响[J].儿科药学杂志,2017,23(8):29-32.
[2]Gordon VM.OC-017 Multi-centre audit of management and outcome in autoimmune hepatitis(aih)-preliminary results[J].J Hepatology,2015,62(S1):S788-S789.
[3]谭义林,叶池林.布地奈德雾化吸入联合阿奇霉素对支原体肺炎患儿肺功能及血清炎症因子、免疫功能的影响[J].海南医学院学报,2016,22(22):2782-2784,2788.
[4]彭燕,王策,黄燕,等.孟鲁司特钠联合布地奈德对儿童咳嗽变异性哮喘的临床效果及炎症因子的影响[J].中国妇幼保健,2015,30(32):5688-5689.
[5]胡波.盐酸氨溴索联合布地奈德治疗小儿支气管肺炎的临床疗效及其对C反应蛋白和白细胞计数的影响[J].实用心脑肺血管病杂志,2015,23(8):68-70.
[6]吴玲玲.布地奈德吸入联合孟鲁司特钠对小儿哮喘疗效及炎症因子的影响[J].中国妇幼保健,2017,32(1):191-194.
[7]吴海丽,李贤斌.气雾型布地奈德联合孟鲁司特钠治疗小儿咳嗽变异性哮喘疗效及对肺功能和血清炎症因子的影响[J].海南医学院学报,2016,22(5):467-469,473.
[8]林寒梅.孟鲁司特钠联合布地奈德治疗儿童咳嗽变异性哮喘临床疗效及对炎症因子的影响[J].中国妇幼保健,2015,30(5):796-797.
[9]赵家艳,扈雯雯,柳晓艳,等.阿奇霉素联合红霉素对小儿支原体肺炎细胞因子及免疫球蛋白的影响[J].中国合理用药探索,2017,14(110:14-16.
[10]杨秋丽,郑小翠.布地奈德混悬液联合妥洛特罗治疗小儿喘息性肺炎的疗效及对血清细胞因子水平炎症指标的影响[J].山西医药杂志,2017,46(1)73-75.
[11]Harbord M,Annese V,Vavricka SR,et al.The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease[J].J Crohns Colitis,2016,10(3):239-254.
[12]胡宏凯.纤支镜吸痰疗法联合抗感染治疗对重症肺部感染患者呼吸指标及炎性应激情况的作用分析[J].中国合理用药探索,2017,14(11):8-11.
[13]Cazzola M,Beeh KM,Price D,et al.Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD[J].Pulm Pharmacol Ther,2015,31:68-78.
[2]Gordon VM.OC-017 Multi-centre audit of management and outcome in autoimmune hepatitis(aih)-preliminary results[J].J Hepatology,2015,62(S1):S788-S789.
[3]谭义林,叶池林.布地奈德雾化吸入联合阿奇霉素对支原体肺炎患儿肺功能及血清炎症因子、免疫功能的影响[J].海南医学院学报,2016,22(22):2782-2784,2788.
[4]彭燕,王策,黄燕,等.孟鲁司特钠联合布地奈德对儿童咳嗽变异性哮喘的临床效果及炎症因子的影响[J].中国妇幼保健,2015,30(32):5688-5689.
[5]胡波.盐酸氨溴索联合布地奈德治疗小儿支气管肺炎的临床疗效及其对C反应蛋白和白细胞计数的影响[J].实用心脑肺血管病杂志,2015,23(8):68-70.
[6]吴玲玲.布地奈德吸入联合孟鲁司特钠对小儿哮喘疗效及炎症因子的影响[J].中国妇幼保健,2017,32(1):191-194.
[7]吴海丽,李贤斌.气雾型布地奈德联合孟鲁司特钠治疗小儿咳嗽变异性哮喘疗效及对肺功能和血清炎症因子的影响[J].海南医学院学报,2016,22(5):467-469,473.
[8]林寒梅.孟鲁司特钠联合布地奈德治疗儿童咳嗽变异性哮喘临床疗效及对炎症因子的影响[J].中国妇幼保健,2015,30(5):796-797.
[9]赵家艳,扈雯雯,柳晓艳,等.阿奇霉素联合红霉素对小儿支原体肺炎细胞因子及免疫球蛋白的影响[J].中国合理用药探索,2017,14(110:14-16.
[10]杨秋丽,郑小翠.布地奈德混悬液联合妥洛特罗治疗小儿喘息性肺炎的疗效及对血清细胞因子水平炎症指标的影响[J].山西医药杂志,2017,46(1)73-75.
[11]Harbord M,Annese V,Vavricka SR,et al.The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease[J].J Crohns Colitis,2016,10(3):239-254.
[12]胡宏凯.纤支镜吸痰疗法联合抗感染治疗对重症肺部感染患者呼吸指标及炎性应激情况的作用分析[J].中国合理用药探索,2017,14(11):8-11.
[13]Cazzola M,Beeh KM,Price D,et al.Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD[J].Pulm Pharmacol Ther,2015,31:68-78.